CD4 Antibody Treatment in Crohn's Disease

References

• Katz K D, Hollander D, Vadheim C M, et al. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989; 97: 927–31
   PubMed Web of Science ®Google Scholar
• Howden C W, Robertson C, Ducan A, Morris A J, Russel R I. Comparison of different measurements of intestinal permeability in inflammatory bowel disease. Am J Gastroenterol 1991; 86: 1445–9
   PubMed Web of Science ®Google Scholar
• Madara J L, Moore R. Carlson S. Alteration of intestinal tight junction structure and permeability by cytoskeletal contraction. AmPhy Soc 1987; C584–61
   Google Scholar
• Ouyang Q, El-Youssef M, Yen-Lieberman B, et al. Expresion of HLA-DR antigens in inflammatory bowel disease mucosa: role of intestinal lamina propria mononuclear cell-derived interferon τ. Dig Dis Sci 1988; 33: 1528–36
   PubMed Web of Science ®Google Scholar
• Cuvelier C, Mielants H, de Vos M, Veys E, Roels H. Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropathy. Gut 1990; 31: 545–9
   PubMedGoogle Scholar
• Mayer L, Eisenhardt D, Salomon P., Bauer W, Pious R, Piccinini L. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel diseases. Gastroenterology 1991; 100: 3–12
   PubMed Web of Science ®Google Scholar
• James S P, Fiocchi C, Greaff A S, Strober W. Phenotypic analysis of lamina propria lymphocytes. Predominance of helper-inducer and cytolytic T-cell phenotypes and deficiency of suppressor-inducer phenotypes in Crohn's disease and control patients. Gastroenterology 1986; 91: 1483–9
   PubMedGoogle Scholar
• Rappaport H, Burgoyne F H, Smetana H F. The pathology of regional enteritis. Milit Surg 1951; 109: 463–502
   PubMedGoogle Scholar
• Zifronini A, Treves A J, Sachar D B, Rachmilewitz D. Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut 1983; 24: 659–65
   PubMedGoogle Scholar
• Ferguson A. Why study T cell subsets in Crohn's disease?. Gut 1983; 24: 687–91
   PubMedGoogle Scholar
• Selby W S, Janossy G, Boflll M, Jewell D P. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut 1984; 25: 32–40
   PubMed Web of Science ®Google Scholar
• Konttinen Y T, Bergroth V, Nordstrom D, Segerberg-Konttinen M, Seppala K, Salaspuro M. Lymphocyte activation in vivo in the intestinal mucosa of patients with Crohn's disease. J Clin Lab Immunol 1987; 22: 59–63
   PubMedGoogle Scholar
• Fais S, Pallone F, Squarcia O, et al. HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: 1. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol 1987; 68: 605–12
   PubMed Web of Science ®Google Scholar
• Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boivirant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by expression of early activation antigens. Gut 1987; 28: 745–53
   PubMed Web of Science ®Google Scholar
• Choy M Y, Walker-Smith J A, Williams C B, MacDonald T T. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 1990; 31: 1365–70
   PubMed Web of Science ®Google Scholar
• Monk T J, Spencer J, Cerf-Bensussan N, MacDonald T T. Activation of mucosal T-cells in situ with anti-CD3 antibody: pheno-type of activated T-cells and their distribution within the mucosal micro-environment. Clin Exp Immunol 1988; 74: 216–22
   PubMedGoogle Scholar
• Brynskov J, Tvede N, Andersen C B, Vilien M. Increased concentrations of interleukin 1β, interleukin-2, and soluble interleukin-2 receptors in endoscopic mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992; 33: 55–8
   PubMed Web of Science ®Google Scholar
• Meuler C H, Knoflach P, Zielinski C C. T-cell activation in Crohn's disease. Gastroenterology 1990; 98: 639–46
   PubMedGoogle Scholar
• Crabtree J E, Juby L D, Heatley R V, Lobo A J, Bullimore D W, Axon A TR. Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity. Gut 1990; 31: 1033–6
   PubMed Web of Science ®Google Scholar
• Mahida Y R, Callager A, Kurlak L, Hawkey C Y. Plasma and tissue interleukin-2 receptor level in IBD. Clin Exp Immunol 1990; 82: 75–80
   PubMedGoogle Scholar
• Senju M, Hulstaert F, Lowder J, Jewell D P. Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease. Gut 1991; 32: 779–83
   PubMed Web of Science ®Google Scholar
• Cher D J, Mosman T R. Two types of murine T cell clone. II. Delayed type hypersensitivity is mediated by Thl clones. J Immunol 1987; 138: 3688–94
   PubMed Web of Science ®Google Scholar
• Ashwell D J, Fox B S, Schwartz R H. Tcell recognition of antigen and la molecules involves a trimolecular complex. Processing and presentation of antigens. Academic Press, London 1988
   Google Scholar
• Atalla L, Linker-Israeli M, Steinman L, Rao N A. Inhibition of autoimmune uveitis by Anti-CD4 antibody. Invest Ophthalmol Vis Sci 1990; 31: 1264–70
   PubMed Web of Science ®Google Scholar
• Hafler D A, Fallis R J, Dawson D M, Schlossman S F, Reinherz E L, Weiner H L. Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology 1986; 36: 777–84
   PubMed Web of Science ®Google Scholar
• Ortho Multicenter Transplantation Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337–42
   PubMedGoogle Scholar
• Catane R, Longo D L. Monoclonal antibodies for cancer therapy. Isr J Med Sci 1988; 24: 471–6
   PubMedGoogle Scholar
• Alters S E, Sakai K, Steinman L, Oi V T. Mechanisms of anti-CD-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies. J Immunol 1990; 144: 4587–92
   PubMedGoogle Scholar
• James S P. Remission of Crohn's disease after human immunodeficiency virus infection. Gastroenterology 1988; 95: 1667–9
   PubMed Web of Science ®Google Scholar
• Herzog C, Walker C, Müller W, et al. Anti-CD4 antibody treatment of patients with Rheumatoid arthritis. I. Effect on clinical course and circulating T cells. J Autoimmun 1989; 2: 627–42
   PubMedGoogle Scholar
• Walker C, Herzog C, Rieber P, Rietmüller G, Müller W, Pichler W J. Anti-CD4 antibody treatment of patients with rheumatoid arthritis. II. Effect of in vivo treatment on in vitro proliverative response of CD4 cells. J Autoimmun 1989; 2: 643–9
   PubMedGoogle Scholar
• O'Brien J J, Bayless T M, Bayless J A. Use of azathioprine or 6-mercaptopurine in treatment of Crohn's disease. Gastroenterology 1991; 101: 39–46
   PubMed Web of Science ®Google Scholar
• Hess A D, Colombani P M. Cyclosporin: mechanism of action: in vitro studies. Prog Allergy 1986; 38: 198–221
   PubMedGoogle Scholar
• Brynskov J, Freund L, Rasmussen S N, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 845–50
   PubMed Web of Science ®Google Scholar
• Asano M, Minagawa T, Ohamichi M, Hiraga Y. Detection of endogenous cytokines in sera or lymph nodes obtained from patients with sarcoidosis. Clin Exp Immunol 1991; 84: 92–6
   PubMed Web of Science ®Google Scholar
• Ruco L P, Stoppacciaro A, Pomponi D, et al. Immunoreactivity for IL-1 beta and TNF alpha in human lymphoid and non-lymphoid tissues. Am J Pathol 1989; 135: 889–97
   PubMed Web of Science ®Google Scholar
• Dunn C J, Hardee M M, Staite N D. Acute and chronic inflammatory responses to local administration of recombinant IL-1 alpha, IL-beta, TNF alpha, IL-2 and Ifn gamma in mice. Agents Actions 1989; 27: 290–3
   PubMedGoogle Scholar
• Kindler V., Sappino A P, Grau G, Piguet P F, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731–40
   PubMed Web of Science ®Google Scholar
• MacDonald T T, Hutchings P, Choy M-Y, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301–5
   PubMed Web of Science ®Google Scholar
• Braegger C P, Nicholls S, Murch S H, Stephens S, MacDonald T T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89–91
   PubMed Web of Science ®Google Scholar
• Exley A R, Cohen J, Buurman W, et al. Monoclonal antibody to TNF in severe septic shock. Lancet 1990; 335: 1275–7
   PubMed Web of Science ®Google Scholar
• Schönharting M M., Schade U F. The effect of pentoxyfilline in septic shock–new pharmacological aspects of an established drug. J Med 1989; 20: 97–105
   PubMedGoogle Scholar
• Schade U F. Pentoxyfylline increases survival in murine endo-toxine shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31: 171–81
   PubMedGoogle Scholar
• Strieter R M, Remick D G, Ward P A, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxyfilline. Biochem Biophys Res Commun 1988; 155: 1230–6
   PubMed Web of Science ®Google Scholar
• Sullivan G W, Carper H T, Novick W J, Mandell G L. Inhibition of inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by Pentoxifylline. Infect Immun 1988; 56: 1722–9
   PubMed Web of Science ®Google Scholar
• Sampaio E P, Sarno E N, Galilly R, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699–703
   PubMed Web of Science ®Google Scholar
• Mahida Y R, Wu K, Jewel D P. Enhanced production of interleukin 1-β by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease. Gut 1989; 30: 835–8
   PubMed Web of Science ®Google Scholar
• Kusugami K, Youngman K R, West G A, Fiocchi C. Intestinal immune reactivity to interleukin 2 differs among Crohn's disease, ulcerative colitis and controls. Gastroenterology 1989; 97: 1–9
   PubMedGoogle Scholar
• Mathew R C, Ragheb S, Boros D L. Recombinant IL-2 therapy reverses diminished granulomatous responsiveness in anti-L3T4-treated, Schistosoma mansom'-infected mice. J Immunol 1990; 144: 4356–61
   PubMed Web of Science ®Google Scholar
• Peyronnet P, Le Mauff B, Hourmant M, et al. Prophylactic treatment of human kidney allograt recipients with a monoclonal antibody (33B3.1) directed against interleukin 2 receptor. Transplant Proc 1988; 20: 300–2
   PubMedGoogle Scholar
• Dinarello C A. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–52
   PubMed Web of Science ®Google Scholar
• Ohlsson K, Bjork P, Bergenfeldt M, et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550–2
   PubMed Web of Science ®Google Scholar
• Wakabayashi G, Gelfand J G, Burke J F, et al. A specific receptor antagonist for interleukin-1 prevents Ecoli-induced shock in rabbits. FASEB J 1991; 5: 338–43
   PubMed Web of Science ®Google Scholar
• Curfs J HAJ., Vogels M TE, Eling W MC, . IL-1 receptor antagonist prevents cerebral malaria in Plasmodium berghei-infected mice. The pathophysiology and pharmacology of cytokines, A Mantovani, P Ghezzi, et al. Biomedical Press, New York 1992
   Google Scholar